← Leaderboards
Brent R Stockwell
Whitehead Institute For Biomedical Res
$20,923,379
Attributed
$22,849,297
Total exposure
16
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,280,661 · 17
By mechanism
P01$12,151,244 · 4
R01$9,211,836 · 4
R35$6,473,423 · 1
UH3$1,350,000 · 1
P30$894,627 · 1
R33$777,642 · 1
Top collaborators
- Adolfo A. Ferrando5 shared
- Carol Prives5 shared
- Hua Tian5 shared
Most similar at Whitehead Institute For Biomedical Res
Same institution · by research overlap
- Wei Tong$21,627,247
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsPathway InteractionsProteinsCell DeathMutantTumorMalignant NeoplasmsSignal TransductionSmall MoleculeMolecularResponseIn VitroPharmaceutical PreparationsBaseMediatingInhibitor/AntagonistApoptosisNeoplastic CellMutationInsightLeadGenesResistanceLipid Peroxidation
Grant awards (64)
Project 2: Targeting Specific Lipid Species that Drive Ferroptosis Resistance$639,770
P01 · FY2025 · CA · contact PI
Shared Resources Core: Ferroptosis Biomarkers and Lipidomic Analysis$326,204
P01 · FY2025 · CA · contact PI
Proteomics and Macromolecular Crystallography Shared Resource$223,656
P30 · FY2024 · CA · contact PI
Multimodal mass spectrometry imaging of mouse and human liver$600,000
UH3 · FY2023 · CA · contact PI
Proteomics and Macromolecular Crystallography Shared Resource$223,657
P30 · FY2023 · CA · contact PI
Multimodal mass spectrometry imaging of mouse and human liver$150,000
UH3 · FY2023 · CA · contact PI
Defining the functions and translational potential of ferroptosis$926,481
R35 · FY2022 · CA · contact PI
Multimodal mass spectrometry imaging of mouse and human liver$600,000
UH3 · FY2022 · CA · contact PI
Development of ferroptosis inhibitors for Huntington Disease$388,068
R33 · FY2022 · NS · contact PI
Proteomics and Macromolecular Crystallography Shared Resource$223,657
P30 · FY2022 · CA · contact PI
Roles and Regulation of wild-type and mutant forms of p53$1,885,586
P01 · FY2021 · CA
Defining the functions and translational potential of ferroptosis$955,184
R35 · FY2021 · CA · contact PI
Development of ferroptosis inhibitors for Huntington Disease$389,574
R33 · FY2021 · NS · contact PI
Molecular characterization and targeting of NT5C2 mutations in acute lymphoblastic leukemia$383,548
R01 · FY2021 · CA
Project 2: Probing the role of the p53 network in ferroptosis$352,899
P01 · FY2021 · CA · contact PI
Multimodal mass spectrometry imaging of mouse and human liver$300,000
UG3 · FY2021 · CA · contact PI
Proteomics and Macromolecular Crystallography Shared Resource$223,657
P30 · FY2021 · CA · contact PI
Roles and Regulation of wild-type and mutant forms of p53$1,885,586
P01 · FY2020 · CA
Defining the functions and translational potential of ferroptosis$955,184
R35 · FY2020 · CA · contact PI
Molecular characterization and targeting of NT5C2 mutations in acute lymphoblastic leukemia$383,193
R01 · FY2020 · CA
Project 2: Probing the role of the p53 network in ferroptosis$352,898
P01 · FY2020 · CA · contact PI
Multimodal mass spectrometry imaging of mouse and human liver$300,000
UG3 · FY2020 · CA · contact PI
Roles and Regulation of wild-type and mutant forms of p53$1,829,019
P01 · FY2019 · CA
Defining the functions and translational potential of ferroptosis$916,929
R35 · FY2019 · CA · contact PI
Development of ferroptosis inhibitors for Huntington Disease$400,327
R61 · FY2019 · NS · contact PI
Molecular characterization and targeting of NT5C2 mutations in acute lymphoblastic leukemia$371,168
R01 · FY2019 · CA
Project 2: Probing the role of the p53 network in ferroptosis$342,311
P01 · FY2019 · CA · contact PI
Roles and Regulation of wild-type and mutant forms of p53$1,885,586
P01 · FY2018 · CA
Defining the functions and translational potential of ferroptosis$955,184
R35 · FY2018 · CA · contact PI
Molecular characterization and targeting of NT5C2 mutations in acute lymphoblastic leukemia$382,254
R01 · FY2018 · CA
Project 2: Probing the role of the p53 network in ferroptosis$352,900
P01 · FY2018 · CA · contact PI
Roles and Regulation of wild-type and mutant forms of p53$1,945,587
P01 · FY2017 · CA
Defining the functions and translational potential of ferroptosis$955,184
R35 · FY2017 · CA · contact PI
Molecular characterization and targeting of NT5C2 mutations in acute lymphoblastic leukemia$381,673
R01 · FY2017 · CA
Project 2: Probing the role of the p53 network in ferroptosis$352,898
P01 · FY2017 · CA · contact PI
Defining the functions and translational potential of ferroptosis$809,277
R35 · FY2016 · CA · contact PI
Chemical genetic profiling of engineered tumor cells$350,176
R01 · FY2016 · CA · contact PI
Chemical genetic profiling of engineered tumor cells$350,176
R01 · FY2015 · CA · contact PI
Discovery of allele-selective KRAS inhibitors$171,252
R21 · FY2015 · CA · contact PI
Chemical genetic profiling of engineered tumor cells$339,671
R01 · FY2014 · CA · contact PI
Comparing HTS with Fragment-Based Design for B-Raf and the Ras-Raf Interaction$253,835
R01 · FY2014 · CA · contact PI
Discovery of allele-selective KRAS inhibitors$200,310
R21 · FY2014 · CA · contact PI
Chemical genetic profiling of engineered tumor cells$350,176
R01 · FY2013 · CA · contact PI
Comparing HTS with Fragment-Based Design for B-Raf and the Ras-Raf Interaction$245,985
R01 · FY2013 · CA · contact PI
Comparing HTS with Fragment-Based Design for B-Raf and the Ras-Raf Interaction$261,686
R01 · FY2012 · CA · contact PI
Chemical genetic profiling of engineered tumor cells$353,067
R01 · FY2011 · CA · contact PI
Defining a novel trigger for apoptosis$299,813
R01 · FY2011 · GM · contact PI
Comparing HTS with Fragment-Based Design for B-Raf and the Ras-Raf Interaction$261,686
R01 · FY2011 · CA · contact PI
Chemical genetic profiling of engineered tumor cells$61,770
R01 · FY2011 · CA · contact PI
Chemical genetic profiling of engineered tumor cells$363,710
R01 · FY2010 · CA · contact PI
Defining a novel trigger for apoptosis$302,841
R01 · FY2010 · GM · contact PI
Chemical genetic profiling of engineered tumor cells$44,271
R01 · FY2010 · CA · contact PI
Chemical genetic profiling of engineered tumor cells$363,433
R01 · FY2009 · CA · contact PI
Defining a novel trigger for apoptosis$304,792
R01 · FY2009 · GM · contact PI
Defining a novel trigger for apoptosis$268,206
R01 · FY2009 · GM · contact PI
Chemical genetic profiling of engineered tumor cells$363,156
R01 · FY2008 · CA · contact PI
Defining a novel trigger for apoptosis$304,570
R01 · FY2008 · GM · contact PI
Screen for RAS-Selective Lethal Compounds and VDAC Ligands$25,000
R03 · FY2008 · MH · contact PI
Chemical genetic profiling of engineered tumor cells$362,879
R01 · FY2007 · CA · contact PI
Luciferase Screen for MDM2 E3 Ligase Inhibitors$25,000
R03 · FY2007 · MH · contact PI
Chemical Genetic Profiling of Engineered Tumor Cells$363,788
R01 · FY2005 · CA
Chemical Genetic Profiling of Engineered Tumor Cells$363,788
R01 · FY2004 · CA
Chemical Genetic Profiling of Engineered Tumor Cells$422,750
R01 · FY2003 · CA
Chemical Genetic Profiling of Engineered Tumor Cells$353,775
R01 · FY2002 · CA